RPRX in the 13F filings
Royalty Pharma PLC · CUSIP G7709Q104
- Quarter end
- 30 Jun 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 25 Jul 2024
- Managers listing it
- 12
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q1 2024 and Q2 2024; 9 listed it in both
- Shares listed
- 65,630,044
- combined, among listed positions
- Reported value
- $1.7bn
- combined, at the quarter end
Among the 94 comparable managers: 7 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing RPRX in Q2 2024
12 of 12 holders
Largest increases and reductions, by shares
Increases
- Two Sigma Investments LPexisting position · 2,057,540 shares now+753,881
- Two Sigma Advisers LPexisting position · 2,096,300 shares now+573,900
- Viking Global Investors LPexisting position · 11,970,058 shares now+484,511
- Arrowstreet Capital LPexisting position · 940,034 shares now+57,288
- PDT Partners LLCnew position · 51,436 shares now+51,436
Reductions
- Fidelity (FMR LLC)existing position · 27,886,701 shares now-5,747,515
- Marshall Wace LLPexisting position · 945,840 shares now-510,060
- Baillie Gifford & Coexisting position · 16,352,759 shares now-310,033
- Bridgewater Associates LPexisting position · 238,991 shares now-132,471
- Janus Henderson Group Ltdexisting position · 1,767,417 shares now-85,243
New positions and exits
New (1)
- PDT Partners LLC$1.4m
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2020 | 10 | $1.8bn | n.a. | n.a. |
| Q3 2020 | 7 | $1.6bn | n.a. | n.a. |
| Q4 2020 | 5 | $1.9bn | n.a. | n.a. |
| Q1 2021 | 5 | $1.5bn | n.a. | n.a. |
| Q2 2021 | 8 | $1.5bn | n.a. | n.a. |
| Q3 2021 | 6 | $1.4bn | n.a. | n.a. |
| Q4 2021 | 8 | $1.8bn | n.a. | n.a. |
| Q1 2022 | 8 | $1.8bn | n.a. | n.a. |
| Q2 2022 | 10 | $3.2bn | n.a. | n.a. |
| Q3 2022 | 11 | $3.4bn | n.a. | n.a. |
| Q4 2022 | 17 | $3.4bn | n.a. | n.a. |
| Q1 2023 | 14 | $2.9bn | n.a. | n.a. |
| Q2 2023 | 16 | $2.3bn | n.a. | n.a. |
| Q3 2023 | 14 | $1.9bn | n.a. | n.a. |
| Q4 2023 | 13 | $2.1bn | 8 | 6 |
| Q1 2024 | 10 | $2.2bn | 5 | 6 |
| Q2 2024 | 12 | $1.7bn | 7 | 5 |
| Q3 2024 | 10 | $2.0bn | 7 | 4 |
| Q4 2024 | 10 | $1.6bn | 7 | 3 |
| Q1 2025 | 9 | $2.3bn | 4 | 5 |
| Q2 2025 | 9 | $2.4bn | 4 | 5 |
| Q3 2025 | 11 | $1.9bn | 7 | 5 |
| Q4 2025 | 10 | $2.4bn | 17 | 14 |
| Q1 2026 | 15 | $3.1bn | 18 | 16 |
| Q2 2026 | 15 | $3.9bn | 21 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RPRX and LLY →RPRX and JNJ →RPRX and VRTX →Choose a stock to compare with RPRX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RPRX, latest filings →Back to the 13F Explorer →